EHSI incorporates outpatient treatment options into MedAnywhere HHC Module

NewsGuard 100/100 Score

Emerging Healthcare Solutions, Inc. (Pink Sheets: EHSI) revealed today that they are working to incorporate outpatient treatment options into the new MedAnywhere medical iPhone app and that the first module to be added to development will be for cost saving Hemochromatosis (HHC) management. HHC is the disease that occurs as a result of significant iron overload and it can have genetic or non-genetic causes. In the United States about one million people have the disease. HHC can cause major damage to the heart, liver, pancreas, joints and pituitary. If the extra iron is not removed, these organs can become diseased. Untreated Hemochromatosis can be fatal.

Traditionally, HHC treatment requires numerous costly visits to the lab for blood work and expensive phlebotomy treatments performed at hospitals - plus the cost of meetings with the doctor at their office. HHC management is usually for life. MedAnywhere is being configured to allow a customer's Hematocrit levels to be monitored by Bluetooth® compatible hardware at home with a doctor overseeing the treatment via the iPhone. As a result, customers are able to be directed by their doctor to have phlebotomy treatments done at blood donor centers, which usually perform the treatment for no charge. Only a monitoring physician can order the treatment.

The MedAnywhere HHC Module should allow many patient/customers to realize savings of thousands or even tens of thousands of dollars as a result.

SOURCE Emerging Healthcare Solutions, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study findings better define the genetic landscape of neuroendocrine tumors of the cervix